Definiens, Cernostics Team on Multiplex Cancer Tests | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Definiens and Cernostics today announced that they will collaborate on the development of multiplex molecular diagnostics tests for a variety of cancers.

Danville, Pa.-based Cernostics will use Definiens' Tissue Studio digital pathology technology to develop the tests. The Definiens technology enables pathologists to analyze cancers on the cellular and sub-cellular level, the firms said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.